Compare · NAGE vs RGC
NAGE vs RGC
Side-by-side comparison of Niagen Bioscience Inc. (NAGE) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAGE and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $4.72B, about 23.1x NAGE ($204.1M).
- NAGE has been more active in the news (6 items in the past 4 weeks vs 1 for RGC).
- NAGE has more recent analyst coverage (1 ratings vs 0 for RGC).
- Company
- Niagen Bioscience Inc.
- Regencell Bioscience Holdings Limited
- Price
- -
- -
- Market cap
- $204.1M
- $4.72B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 1
- Recent ratings
- 1
- 0
Latest NAGE
- Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
- Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
- Niagen Bioscience to Present at LD Micro 20th Annual Main Event
- Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
- Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
- Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
- Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
- Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
- Niagen Bioscience to Present at Longevity Investors Conference
- Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
Latest RGC
- SEC Form 20-F filed by Regencell Bioscience Holdings Limited
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited